Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Molecular Stratification of Chronic Kidney Disease

Anna Reznichenko, Viji Nair, View ORCID ProfileSean Eddy, Mark Tomilo, Timothy Slidel, Wenjun Ju, James P. Conway, Shawn S. Badal, Johnna Wesley, John T. Liles, Sven Moosmang, Julie M. Williams, Carol Moreno Quinn, Markus Bitzer, Anil Karihaloo, Matthew D. Breyer, Kevin L. Duffin, Uptal D. Patel, Maria Chiara Magnone, Ratan Bhat, Matthias Kretzler
doi: https://doi.org/10.1101/2021.09.09.21263234
Anna Reznichenko
1Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anna.reznichenko{at}astrazeneca.com kretzler{at}umich.edu
Viji Nair
2Michigan Medicine, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Eddy
2Michigan Medicine, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sean Eddy
Mark Tomilo
2Michigan Medicine, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Slidel
3Early Computational Oncology, Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenjun Ju
2Michigan Medicine, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James P. Conway
4Early Computational Oncology, Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Gaithersburg, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn S. Badal
5Gilead Sciences, Foster City, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johnna Wesley
6Global Diabetes, Cardio-renal and Translational Research, NovoNordisk, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John T. Liles
5Gilead Sciences, Foster City, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven Moosmang
1Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie M. Williams
7Bioscience Renal, Research and Early Development, Cardiovascular, Renal & Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol Moreno Quinn
8Medical Affairs, Vifor Pharma, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Bitzer
2Michigan Medicine, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anil Karihaloo
6Global Diabetes, Cardio-renal and Translational Research, NovoNordisk, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew D. Breyer
9Cardiovascular and Metabolism Therapeutic Area, Janssen Research and Development LLC, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin L. Duffin
10Diabetes, Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uptal D. Patel
3Early Computational Oncology, Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Chiara Magnone
9Cardiovascular and Metabolism Therapeutic Area, Janssen Research and Development LLC, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ratan Bhat
11Search and Evaluation, Cardiovascular Renal & Metabolism, Business Development & Licensing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Kretzler
2Michigan Medicine, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anna.reznichenko{at}astrazeneca.com kretzler{at}umich.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Current classification of chronic kidney disease (CKD) into stages based on the indirect measures of kidney functional state, estimated glomerular filtration rate and albuminuria, is agnostic to the heterogeneity of underlying etiologies, histopathology, and molecular processes. We used genome-wide transcriptomics from patients’ kidney biopsies, directly reflecting kidney biological processes, to stratify patients from three independent CKD cohorts. Unsupervised Self-Organizing Maps (SOM), an artificial neural network algorithm, assembled CKD patients into four novel subgroups, molecular categories, based on the similarity of their kidney transcriptomics profiles. The unbiased, molecular categories were present across CKD stages and histopathological diagnoses, highlighting heterogeneity of conventional clinical subgroups at the molecular level. CKD molecular categories were distinct in terms of biological pathways, transcriptional regulation and associated kidney cell types, indicating that the molecular categorization is founded on biologically meaningful mechanisms. Importantly, our results revealed that not all biological pathways are equally activated in all patients; instead, different pathways could be more dominant in different subgroups and thereby differentially influencing disease progression and outcomes. This first kidney-centric unbiased categorization of CKD paves the way to an integrated clinical, morphological and molecular diagnosis. This is a key step towards enabling precision medicine for this heterogeneous condition with the potential to advance biological understanding, clinical management, and drug development, as well as establish a roadmap for molecular reclassification of CKD and other complex diseases.

One sentence summary Unbiased grouping of patients based on kidney biopsy transcriptomics profiles generated a novel molecular categorization of chronic kidney disease.

Competing Interest Statement

Dr. Kretzler reports grants from NIH, non-financial support from University of Michigan, during the conduct of the study; grants from JDRF, Astra-Zeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Merck, Chan Zuckerberg Initiative, Janssen, Boehringer-Ingelheim, Moderna, Chinook, amfAR, Angion, RenalytixAI, Retrophin, European Union Innovative Medicine Initiative and Certa outside the submitted work; In addition, Dr. Kretzler has a patent PCT/EP2014/073413, Biomarkers and methods for progression prediction for chronic kidney disease, licensed. Dr. Eddy has served as co-Investigator on grants funded by Gilead Sciences, NovoNordisk, AstraZeneca, Jannsen and Eli Lilly. Dr. Patel serves on the Board of Directors of Kidney Health Initiative. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. A.R., T.S., J.P.C., S.M., J.M.W., R.B. are employees of AstraZeneca. S.S.B., J.T.L., U.P.D. are employees and J.T.L is a shareholder of Gilead. C.M.Q. is an employee of Vifor Pharma, J.W., A.K. are employees of NovoNordisk. K.L.D. is an employee and stockholder of Eli Lilly and Company. M.D.B., M.C.M. are employees, M.C.M is also a shareholder of Johnson and Johnson.

Funding Statement

This work was done as part of Renal Precompetitive Consortium (RPC2) collaboration (60) and was jointly funded by the participating members. This work is supported, in part, by George M. OBrien Michigan Kidney Translational Core Center, funded by NIH/NIDDK grant P30-DK-081943. The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK-083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research, NCATS, and the National Institute of Diabetes, Digestive, and Kidney Diseases. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, the NephCure Kidney International and the Halpin Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study only uses publicly available data.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

ERCB (European Renal cDNA Bank) data were accessed from GEO accession ID: GSE104954; C-PROBE (Clinical Phenotyping Resource and Biobank Core) tubulointerstitial transcriptomics data generated on Affymetrix Human Genome U133 Plus 2.0 Array were available for 42 patients (GEO accession ID: GSE69438). Affymetrix Human Gene 2.1 ST Array tubulointerstitial transcriptomics data from 107 NEPTUNE (Nephrotic Syndrome Study Network) adult CKD were accessed from GEO accession ID: GSE108112. Tubulointerstitial transcriptomics data from 46 living kidney donors were accessed from GEO accession ID:GSE104954.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Stratification of Chronic Kidney Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Molecular Stratification of Chronic Kidney Disease
Anna Reznichenko, Viji Nair, Sean Eddy, Mark Tomilo, Timothy Slidel, Wenjun Ju, James P. Conway, Shawn S. Badal, Johnna Wesley, John T. Liles, Sven Moosmang, Julie M. Williams, Carol Moreno Quinn, Markus Bitzer, Anil Karihaloo, Matthew D. Breyer, Kevin L. Duffin, Uptal D. Patel, Maria Chiara Magnone, Ratan Bhat, Matthias Kretzler
medRxiv 2021.09.09.21263234; doi: https://doi.org/10.1101/2021.09.09.21263234
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Molecular Stratification of Chronic Kidney Disease
Anna Reznichenko, Viji Nair, Sean Eddy, Mark Tomilo, Timothy Slidel, Wenjun Ju, James P. Conway, Shawn S. Badal, Johnna Wesley, John T. Liles, Sven Moosmang, Julie M. Williams, Carol Moreno Quinn, Markus Bitzer, Anil Karihaloo, Matthew D. Breyer, Kevin L. Duffin, Uptal D. Patel, Maria Chiara Magnone, Ratan Bhat, Matthias Kretzler
medRxiv 2021.09.09.21263234; doi: https://doi.org/10.1101/2021.09.09.21263234

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Nephrology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)